BACKGROUND: Interferon-alpha (IFN-alpha) treatment frequently induces depression, potentially leading to early dose reductions or a shorter duration of treatment, which can adversely affect outcomes, including quality of life. OBJECTIVE: Defining relevant risk factors for IFN-alpha-induced depression is essential in order to identify prophylactic treatment strategies. METHOD: The authors examined whether a functional polymorphism (5-HTTLPR) in the gene encoding the serotonin transporter moderates IFN-alpha-induced depressive symptoms in 1,015 patients with chronic hepatitis C (CHC) receiving pegylated IFN-alpha and ribavirin. Depressive symptoms were assessed at baseline, 12 weeks, and 20 weeks of treatment. RESULTS: Depression symptoms increased during antiviral treatment; 5-HTTLPR genotype moderated IFN-alpha-induced depression symptoms in both non-Hispanic Caucasians and Hispanic patients, although the opposite risk allele was associated with depression in the two populations. CONCLUSION: 5-HTTLPR may moderate risk for the development of depressive symptoms during IFN-alpha therapy for CHC in a population-specific manner.
BACKGROUND: Interferon-alpha (IFN-alpha) treatment frequently induces depression, potentially leading to early dose reductions or a shorter duration of treatment, which can adversely affect outcomes, including quality of life. OBJECTIVE: Defining relevant risk factors for IFN-alpha-induced depression is essential in order to identify prophylactic treatment strategies. METHOD: The authors examined whether a functional polymorphism (5-HTTLPR) in the gene encoding the serotonin transporter moderates IFN-alpha-induced depressive symptoms in 1,015 patients with chronic hepatitis C (CHC) receiving pegylated IFN-alpha and ribavirin. Depressive symptoms were assessed at baseline, 12 weeks, and 20 weeks of treatment. RESULTS:Depression symptoms increased during antiviral treatment; 5-HTTLPR genotype moderated IFN-alpha-induced depression symptoms in both non-Hispanic Caucasians and Hispanic patients, although the opposite risk allele was associated with depression in the two populations. CONCLUSION:5-HTTLPR may moderate risk for the development of depressive symptoms during IFN-alpha therapy for CHC in a population-specific manner.
Authors: S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: B G Pollock; R E Ferrell; B H Mulsant; S Mazumdar; M Miller; R A Sweet; S Davis; M A Kirshner; P R Houck; J A Stack; C F Reynolds; D J Kupfer Journal: Neuropsychopharmacology Date: 2000-11 Impact factor: 7.853
Authors: G Oxenkrug; M Perianayagam; D Mikolich; P Requintina; L Shick; R Ruthazer; D Zucker; P Summergrad Journal: J Neural Transm (Vienna) Date: 2010-12-16 Impact factor: 3.575
Authors: Licínia Ganança; Maria A Oquendo; Audrey R Tyrka; Sebastian Cisneros-Trujillo; J John Mann; M Elizabeth Sublette Journal: Psychoneuroendocrinology Date: 2015-10-19 Impact factor: 4.905
Authors: A K Smith; J S Simon; E L Gustafson; S Noviello; J F Cubells; M P Epstein; D J Devlin; P Qiu; J K Albrecht; C A Brass; M S Sulkowski; J G McHutchinson; A H Miller Journal: Mol Psychiatry Date: 2011-06-21 Impact factor: 15.992
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279